Diffuse large B-cell lymphoma presents as limited-stage disease in approximately 30% of cases. Historically, therapy relied on a combined modality of abbreviated chemotherapy followed by involved-field radiotherapy (IFRT). Due to…
Major progress in the understanding of diffuse large B-cell lymphoma (DLBCL) biology has been made in the last decade. Many specific compounds have now entered early phase clinical trials. However,…
Diffuse large B-cell lymphoma (DLBCL) represents the most common lymphoid malignancy in adults, with a median age of 60 to 70 years. Clinical behavior is usually rapidly aggressive, with extranodal…
Laurie H. Sehn, MD, MPH, Editor Aggressive B-cell lymphoma is a descriptive term that has been applied to histologic subtypes of B-cell lymphoma that exhibit a rapid growth rate with…
Lung cancer continues to be the leading cause of cancer-related mortality in the United States. Brain metastases are a significant problem in patients with lung cancer and have conventionally been…
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by early metastatic spread and responsiveness to initial therapy. The incidence of SCLC has been declining in the United…
With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non–small cell lung…
The treatment of patients with good performance status and advanced stage non–small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents…
Activating mutations in the epidermal growth factor receptor (EGFR) are present in approximately 15% of US patients with lung adenocarcinoma. EGFR tyrosine kinase inhibitors are associated with high response rate…
Anaplastic lymphoma kinase ( ALK ) gene rearrangements occur in a small portion of patients with non–small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the…
